As of the cutoff date of March 31, 2025, GenFleet reported that no dose-limiting toxicities (DLTs) were observed across all dose levels (100-900 mg QD), and the treatment-related adverse events (TRAEs ...

BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA accepted its new drug application filing for ...

We expect investors to focus on Verastem Oncology’s VSTM progress with the development of its pipeline candidates being studied for various cancer indications when it reports first-quarter 2025 ...

Verastem Oncology has shared a different spin on what its near-approval treatment for low-grade serous ovarian cancer (LGSOC) could mean for patients, publishing survey results that dig into the ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

COPIKTRA is an important addition to the evolving treatment paradigm for patients with CLL/SLL and FL. The approval of COPIKTRA for the treatment of relapsed or refractory CLL/SLL after at least two ...

Verastem (NASDAQ:VSTM) has observed the following analyst ratings within the last quarter: According to 4 analyst offering 12-month price targets in the last 3 months, Verastem has an average price ...

The Food and Drug Administration on Thursday granted accelerated approval to Verastem Inc.’s (NASDAQ:VSTM) Avmapki Fakzynja Co-pack, a combination of avutometinib and defactinib for adult patients ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to ...

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for ...